Schrodinger's Wave Equation joebelanger Schrödinger, Inc. (NASDAQ:SDGR) is a biotech company specializing in physics based computational chemistry, along with a traditional pipeline of new medicines being tested in clinical trials. The company went public in February 2020, but had existed before that as a private company since 1990. Over this time, Schrödinger built a differentiated physics-based computational platform to enable the discovery of molecules for drug development. Based on the growth of the sof ...

Schrödinger, Inc. (NASDAQ:SDGR) Q1 2024 Earnings Conference Call May 1, 2024 4:30 PM ET Company Participants Ramy Farid - President and CEO Geoff Porges - CFO Karen Akinsanya - President R&D, Therapeutics Jaren Madden - Senior Vice President, Investor Relations and Corporate Communications Conference Call Participants Michael Yee - Jefferies David Leibowitz - Citi Scott Schoenhaus - KeyBanc Vikram Purohit - Morgan Stanley Conor McKay - BMO Steven Mah - TD Cowen Michael Ryskin - Bank of America Matthew Hewit ...

| --- | --- | --- | --- | |---------------------------------------------|-------|-------|-------| | | | | | | | | | | | Pioneering Computational Molecular Design | | | | | May 2024 | | | | | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.76 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.38 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this company would post a loss of $0.44 per share when it actually produced a loss of $0.32, delivering a surprise of 27.27%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.Schrodinger, which belongs to the Zacks ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________________ FORM 10-Q ________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39206 ________________________________________ ...

Exhibit 99.1 Schrödinger Reports First Quarter 2024 Financial Results First Quarter Total Revenue of $36.6 Million, Software Revenue of $33.4 Million Announces FDA Clearance of Investigational New Drug Application for SGR-3515, a Novel Wee1/Myt1 Inhibitor SGR-1505 and SGR-2921 on Track for Initial Phase 1 Data Readouts in Late 2024 or 2025 New York, May 1, 2024 – Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, to ...

Schrodinger, Inc. (SDGR) reported $74.13 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 30.4%. EPS of -$0.32 for the same period compares to -$0.39 a year ago.The reported revenue represents a surprise of -4.73% over the Zacks Consensus Estimate of $77.8 million. With the consensus EPS estimate being -$0.44, the EPS surprise was +27.27%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare t ...

Start Time: 16:30 January 1, 0000 5:33 PM ET Schrödinger, Inc. (NASDAQ:SDGR) Q4 2023 Earnings Conference Call February 28, 2024, 16:30 PM ET Company Participants Ramy Farid - President and CEO Geoff Porges - CFO Karen Akinsanya - President R&D, Therapeutics Matthew Luchini - Director of IR and Corporate Affairs Conference Call Participants David Lebowitz - Citigroup Vikram Purohit - Morgan Stanley Evan Seigerman - BMO Capital Markets Scott Schoenhaus - KeyBanc Chad Wiatrowski - TD Cowen Operator Welcome to ...

Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.39 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 27.27%. A quarter ago, it was expected that this company would post a loss of $0.69 per share when it actually produced a loss of $0.86, delivering a surprise of -24.64%.Over the last four quarters, the company has surpa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Exact name of Registrant as specified in its Charter) _______________________________________ Washington, D.C. 20549 _______________________________________ FORM 10-K _______________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION ...